Myeloproliferative Neoplasm Drugs Market, by Drug Class (Demethylation Agents, Tyrosine kinase Inhibitor, Multikinase Inhibitors, JAK2 Inhibitor, and Others), by Indication (Ph+ Chronic myelogenous leukemia (CML), Ph- Myeloproliferative Neoplasms (MPNs) (

Myeloproliferative Neoplasm Drugs Market, by Drug Class (Demethylation Agents, Tyrosine kinase Inhibitor, Multikinase Inhibitors, JAK2 Inhibitor, and Others), by Indication (Ph+ Chronic myelogenous leukemia (CML), Ph- Myeloproliferative Neoplasms (MPNs) (Myelofibrosis (MF), Polycythemia Vera (PV), Essential Thrombocythemia (ET)), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Myeloproliferative neoplasms (MPNs) are a type of rare blood cancers, which leads to production of excess red blood cells, white blood cells, or platelets in the bone marrow of individuals. Myelo refers to bone marrow and spinal cord of the individual and proliferative describes the rapid growth of blood cells, whereas neoplasm describes the abnormal and uncontrolled growth of cells in patients. The overproduction of blood cells is often associated with a somatic mutation, for example, the over production of JAK2 (Janus kinase 2) leads to chronic myeloproliferative disorders. The various drug classes indicated for the treatment of myeloproliferative neoplasm are demethylation agents, tyrosine kinase inhibitor, multikinase inhibitors, JAK2 inhibitor, and others.
Market Dynamics
Key companies are focusing on strategies such as mergers and acquisitions, which is expected to drive the global myeloproliferative neoplasm drugs market growth. For instance, in January 2019, Takeda Pharmaceutical Company Limited acquired Shire Inc (a biopharmaceutical company in U.K.),to expand its geographical presence in the market and enhance its product portfolio through research and development activities.

Moreover, key players are focusing on product launches and product approvals to strengthen their presence in the global myeloproliferative neoplasm drugs market. For instance, in November 2018, Pfizer Inc. received the U.S. Food and Drug Administration approval for Daurismo for use in adults with acute myeloid leukemia (AML) in 75 years or older patients.
Furthermore, in December 2017, Pfizer Inc. received the U.S. Food and Drug Administration (FDA) approval for a supplemental New Drug Application (sNDA) to expand the indication of BOSULIF (bosutinib) to include adult patients with newly-diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML).
Key features of the study:
This report provides in-depth analysis of the global myeloproliferative neoplasm drugs market, and provides market size (US$ Mn) and compound annual growth rate (CAGR) (%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market. It provides valuable insights about market drivers, restraints, opportunities, country outlook, and competitive strategies adopted by the leading players.
It profiles leading players in the global myeloproliferative neoplasm drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, key developments, and future plans
Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future market expansion and marketing tactics
The global myeloproliferative neoplasm drugs market report caters to various stakeholders in this industry, including investors, product developers and manufacturers, distributors, healthcare organizations, research institutes, new entrants, and financial analysts
Stakeholders would greatly benefit in decision making through various strategy matrices used in analyzing the global myeloproliferative neoplasm drugs market
Detailed Segmentation:
Global Myeloproliferative Neoplasm Drugs Market, By Drug Class:
Demethylation Agents
Tyrosine kinase Inhibitor
Multikinase Inhibitors
JAK2 Inhibitor
Others
Global Myeloproliferative Neoplasm Drugs Market, By Indication:
Ph+ Chronic myelogenous leukemia (CML)
Ph- Myeloproliferative Neoplasms (MPNs)
Myelofibrosis (MF)
Polycythemia Vera (PV)
Essential thrombocythemia (ET)
Global Myeloproliferative Neoplasm Drugs Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Myeloproliferative Neoplasm Drugs Market, By Region:
North America
By Drug Class:
Demethylation Agents
Tyrosine kinase Inhibitor
Multikinase Inhibitors
JAK2 Inhibitor
Others
By Indication:
Ph+ Chronic myelogenous leukemia (CML)
Ph- Myeloproliferative Neoplasms (MPNs)
Myelofibrosis (MF)
Polycythemia Vera (PV)
Essential thrombocythemia (ET)
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
U.S.
Canada
Latin America
By Drug Class:
Demethylation Agents
Tyrosine kinase Inhibitor
Multikinase Inhibitors
JAK2 Inhibitor
Others
By Indication:
Ph+ Chronic myelogenous leukemia (CML)
Ph- Myeloproliferative Neoplasms (MPNs)
Myelofibrosis (MF)
Polycythemia Vera (PV)
Essential thrombocythemia (ET)
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Drug Class:
Demethylation Agents
Tyrosine kinase Inhibitor
Multikinase Inhibitors
JAK2 Inhibitor
Others
By Indication:
Ph+ Chronic myelogenous leukemia (CML)
Ph- Myeloproliferative Neoplasms (MPNs)
Myelofibrosis (MF)
Polycythemia Vera (PV)
Essential thrombocythemia (ET)
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Drug Class:
Demethylation Agents
Tyrosine kinase Inhibitor
Multikinase Inhibitors
JAK2 Inhibitor
Others
By Indication:
Ph+ Chronic myelogenous leukemia (CML)
Ph- Myeloproliferative Neoplasms (MPNs)
Myelofibrosis (MF)
Polycythemia Vera (PV)
Essential thrombocythemia (ET)
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Drug Class:
Demethylation Agents
Tyrosine kinase Inhibitor
Multikinase Inhibitors
JAK2 Inhibitor
Others
By Indication:
Ph+ Chronic myelogenous leukemia (CML)
Ph- Myeloproliferative Neoplasms (MPNs)
Myelofibrosis (MF)
Polycythemia Vera (PV)
Essential thrombocythemia (ET)
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country/Region:
GCC
Israel
Rest of Middle East
Africa
By Drug Class:
Demethylation Agents
Tyrosine kinase Inhibitor
Multikinase Inhibitors
JAK2 Inhibitor
Others
By Indication:
Ph+ Chronic myelogenous leukemia (CML)
Ph- Myeloproliferative Neoplasms (MPNs)
Myelofibrosis (MF)
Polycythemia Vera (PV)
Essential thrombocythemia (ET)
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles
Novartis International AG.*
Company Overview
Material Portfolio
Financial Performance
Key Highlights
Market Strategies
Bristol - Myers Squibb
Pfizer, Inc.
Takeda Pharmaceutical Company Limited
Incyte
Johnson & Johnson
Teva Pharmaceutical Industries Ltd.
F. Hoffmann-La Roche AG
Gamida Cell
Sierra Oncology, Inc.
CTI BioPharma Corp.
Imago BioSciences
AbbVie Inc.
Constellation Pharmaceuticals

“*” marked represents similar segmentation in other categories in the respective section.